Answers are grounded in this paper and cite their sources.
Randomized clinical trials often have characteristics that make them not useful for health care decision making. Such trials leave it open if shortterm benefits remain over longer periods and they often do not provide information on long-term safety or rare or late-occurring events. While more patient-relevant outcomes, such as stroke, disability, or mortality would often be desirable, combined end points or surrogate outcomes are typically the only feasible option within limited follow-up periods; however, they come with other problems and assumptions.
No takes yet. Share an insight, caveat, or question.
Lars G. Hemkens (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: